-
1977
Launched Krestin®, an anticancer drug
-
1980
Launched Cefmetazon®, a cephamycin-type antibiotic
-
1983
Launched Captoril®, the world's first renin-angiotensin-type hypertensive drug
-
1984
Launched Zantac®, a therapeutic agent for peptic ulcers
-
1985
Established Sankyo USA Corporation in New York City
Established Sankyo Europe GmbH in Dusseldorf, Germany
-
1986
Launched Loxonin®, an analgesic and anti-inflammatory agent
-
1987
Established plant in Onahama, Japan
-
1988
Launched Regain®, a mini-bottled vitamin tonic
-
1989
Globally launched Mevalotin®, a groundbreaking HMG-CoA reductase inhibitor (hyperlipidemic drug)
Launched antibiotic agent Banan®
-
1990
Invested in Luitpold-Werk GmbH Group
-
1992
Awarded the Ohkochi Memorial Grand Production Prize for Mevalotin®
-
1994
Completed construction of head office building in Nihonbashi, Japan
-
1994
Launched Acecol®, an antihypertensive agent
-
1996
Established Sankyo Pharma Inc. in New Jersey, United States
-
1998
Became the first pharmaceutical company in Japan to receive ISO 14001 environmental certification for its Onahama and Odawara plants
Established Sankyo Pharma Research Institute in California, United States for the development of new medicines
-
2002
Launched Fastic®, a drug for lowering blood sugar
-
2002
Launched Olmesartan (Benicar® in the United States and Olmetec® in Germany), an antihypertensive agent
-
2003
Launched Calblock®, a long-acting calcium channel blocker
-
2004
Launched Olmesartan in Japan